Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Common Equity (2016 - 2025)

Cytokinetics (CYTK) has disclosed Common Equity for 16 consecutive years, with -$659.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity changed N/A to -$659.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$659.6 million, a N/A change, with the full-year FY2025 number at -$659.6 million, changed N/A from a year prior.
  • Common Equity was -$659.6 million for Q4 2025 at Cytokinetics, down from -$521.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $249.0 million in Q3 2021 to a low of -$659.6 million in Q4 2025.
  • A 5-year average of -$148.6 million and a median of -$107.9 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 575.69% in 2022, then crashed 3646.12% in 2025.
  • Cytokinetics' Common Equity stood at $243.9 million in 2021, then crashed by 144.25% to -$107.9 million in 2022, then tumbled by 258.04% to -$386.3 million in 2023, then surged by 96.4% to -$13.9 million in 2024, then crashed by 4641.75% to -$659.6 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Common Equity are -$659.6 million (Q4 2025), -$521.1 million (Q3 2025), and -$368.7 million (Q2 2025).